Skip to main content

For the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

FOR US HEALTHCARE PROFESSIONALS ONLY

Request a Rep Referral Form
Skip to main content
Referral Form

GETTING STARTED

Setting your patients up for success

  1. Set realistic expectations

    • As the patient titrates, they may not see immediate clinical improvements2,3

    Explain importance of titrating to realize full benefits4

  2. Prepare for common AEs

    • Review AEs (eg, cough, headache, and throat irritation) and why they may occur5
    • Give patients specific instructions to proactively manage any AEs that occur
    • Complete AE Management section on the Referral Form

    Stress that they should not stop treatment without consulting you

  3. Ensure patients understand the dosing plan

    • TYVASO DPI can be titrated by starting with 16 mcg (1 cartridge) 4x daily and increasing by 16 mcg every 1-2 weeks6
    • TYVASO can be titrated by starting with 3 breaths per treatment session and increasing by 3 breaths every 1-2 weeks2
    • There is no maximum labeled dose with TYVASO or TYVASO DPI2,6
    • Once reaching their maintenance dose, the patient should maintain that dose with each treatment session2,6

    Emphasize the importance of completing all 4 daily treatment sessions

You can help patients understand what to expect by walking them through the Referral Form.

AE=adverse event; DPI=dry powder inhaler.